Zacks Research Analysts Decrease Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities research analysts at Zacks Research cut their Q4 2024 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Monday, October 14th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.77 per share for the quarter, down from their prior estimate of $2.78. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.45 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.86 EPS, Q3 2025 earnings at $2.97 EPS and Q3 2026 earnings at $2.94 EPS.

Other research analysts have also recently issued reports about the stock. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target on the stock. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $401.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. Finally, Citigroup raised shares of Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $400.00 in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $368.20.

Bio-Rad Laboratories Trading Down 3.6 %

Shares of BIO stock opened at $329.95 on Tuesday. The stock has a market cap of $9.41 billion, a price-to-earnings ratio of -31.85 and a beta of 0.95. The company has a quick ratio of 4.63, a current ratio of 6.28 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a fifty-two week low of $261.59 and a fifty-two week high of $364.24. The firm’s 50 day moving average price is $329.64 and its two-hundred day moving average price is $306.99.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.99. The firm had revenue of $638.50 million during the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. Bio-Rad Laboratories’s revenue was down 6.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.00 earnings per share.

Institutional Trading of Bio-Rad Laboratories

Several institutional investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Wahed Invest LLC raised its holdings in Bio-Rad Laboratories by 14.0% in the first quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 49 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its holdings in Bio-Rad Laboratories by 7.7% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock valued at $289,000 after acquiring an additional 60 shares in the last quarter. Capital Advisors Ltd. LLC increased its stake in Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares during the last quarter. Finally, Natixis increased its stake in Bio-Rad Laboratories by 3.4% during the first quarter. Natixis now owns 1,986 shares of the medical research company’s stock valued at $687,000 after purchasing an additional 65 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.